Rigel Pharmaceuticals | RIGL - Операционный доход





Операционный доход Изменить Дата
Agenus USD 14.4M 19.26M 2025-12
Amgen USD 3.83B 130M 2026-03
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD -141.26M 182.07M 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Celldex Therapeutics USD -84.44M 2.72M 2026-03
Daiichi Sankyo JPY 89.54B 42.01B 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Halozyme Therapeutics USD -61.77M 26.64M 2026-03
Heron Therapeutics USD 38K 3.83M 2025-12
Intrexon USD -60.84M 26.62M 2024-06
Ionis Pharmaceuticals USD -118M 97M 2026-03
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
Ligand Pharmaceuticals USD 60.33M 40.29M 2026-03
MacroGenics USD -12.1M 30.74M 2025-12
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Pfizer USD 4.99B 340M 2026-03
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Veracyte USD 19.08M 5.55M 2026-03